Editorial: Community Series in Engineered Immune Cells in Cancer Immunotherapy (EICCI), volume II

Front Immunol. 2026 Apr 20:17:1833581. doi: 10.3389/fimmu.2026.1833581. eCollection 2026.

Axel Schambach^{1

2}, Francisco Martin^{3

4

5}, Cristina Maccalli⁶

¹ Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.
² Division of Hematology/Oncology, Boston Children's Hospital, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States.
³ GENYO, Centre for Genomics and Oncological Research, Pfizer, University of Granada, Andalusian Regional Government, Parque Tecnológico Salud (PTS) Granada, Granada, Spain.
⁴ Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain.
⁵ Department of Biochemistry and Molecular Biology III and Immunology, Faculty of Medicine, Excellence Research Unit "Modeling Nature" (MNat), University of Granada, Granada, Spain.
⁶ IRCCS Azienda Ospedaliera Metropolitana Plesso Policlinico San Martino, Genoa, Italy.

No abstract available

Keywords: adoptive cell therapy (ACT); allogeneic cell therapies; chimeric antigen receptor; gene editing; tumor-associated antigens.

Publication types